flanders.bio provides you with insights in the vibrant life sciences sector

 

News from flanders.bio and its members

VIB: Waking up sleeping bacteria to fight infections

Researchers in the group of Jan Michiels (VIB-KU Leuven Center for Microbiology) identified a mechanism of how sleepy bacteria wake up. This finding is important, as sleepy cells are often responsible for the stubbornness of chronic infections. Findings published in Molecular Cell reveal new perspectives on how to treat chronic infections, for example by forcing bacteria to wake up.

Patients | 18 July 19
Read more
18
Jul
2019

VIB: Waking up sleeping bacteria to fight infections

Researchers in the group of Jan Michiels (VIB-KU Leuven Center for Microbiology) identified a mechanism of how sleepy bacteria wake up. This finding is important, as sleepy cells are often responsible for the stubbornness of chronic infections. Findings published in Molecular Cell reveal new perspectives on how to treat chronic infections, for example by forcing bacteria to wake up.

17
Jul
2019

MyCartis and XVIVO Perfusion AB engage to develop a fast diagnostic test to assess the quality of donated organs before transplantation

Today, MyCartis and XVIVO Perfusion AB announce a collaboration to engage in the development of a fast diagnostic tool to timely assess the quality of donated organs during ex-vivo perfusion. Such test can guide the transplant surgeon and team on the quality of an organ and the chances of a positive outcome for the recipient.

17
Jul
2019

Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF

Genkyotexa biopharmaceutical company and the leader in NOX therapies, announced today that the United States Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application allowing the initiation of a Phase 2 trial of the Company’s lead product candidate, GKT831, in patients with idiopathic pulmonary fibrosis (IPF).

16
Jul
2019

Mithra CDMO Strengthens its Management Team and Accelerates Key R&D Programs

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces it has strengthened its CDMO Management team with the appointments of Dr Graham Dixon as Chief Scientific Officer and Mr Renaat Baes as Plant Manager.

15
Jul
2019

Development of a new leishmaniasis drug wins EU funding

TT4CL (Targeted treatment for cutaneous leishmaniasis) is a new Horizon 2020-funded project which aims to reduce the burden of Neglected Infectious Diseases (NID) and its social and economic impacts. Horizon 2020, the European Union’s (EU) research and innovation programme, helps to bridge the gap between preclinical and clinical development and thus helps to advance promising new drug candidates along the development pipeline. The TT4CL consortium, which brings together partners from academia and industry in Europe and disease-endemic countries, has been awarded EUR3.75 million to develop an oral treatment, D121, against one of the most neglected tropical diseases, cutaneous leishmaniasis.

18
Jul
2019

VIB: Waking up sleeping bacteria to fight infections

Researchers in the group of Jan Michiels (VIB-KU Leuven Center for Microbiology) identified a mechanism of how sleepy bacteria wake up. This finding is important, as sleepy cells are often responsible for the stubbornness of chronic infections. Findings published in Molecular Cell reveal new perspectives on how to treat chronic infections, for example by forcing bacteria to wake up.

17
Jul
2019

MyCartis and XVIVO Perfusion AB engage to develop a fast diagnostic test to assess the quality of donated organs before transplantation

Today, MyCartis and XVIVO Perfusion AB announce a collaboration to engage in the development of a fast diagnostic tool to timely assess the quality of donated organs during ex-vivo perfusion. Such test can guide the transplant surgeon and team on the quality of an organ and the chances of a positive outcome for the recipient.

17
Jul
2019

Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF

Genkyotexa biopharmaceutical company and the leader in NOX therapies, announced today that the United States Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application allowing the initiation of a Phase 2 trial of the Company’s lead product candidate, GKT831, in patients with idiopathic pulmonary fibrosis (IPF).

16
Jul
2019

Mithra CDMO Strengthens its Management Team and Accelerates Key R&D Programs

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces it has strengthened its CDMO Management team with the appointments of Dr Graham Dixon as Chief Scientific Officer and Mr Renaat Baes as Plant Manager.

15
Jul
2019

Development of a new leishmaniasis drug wins EU funding

TT4CL (Targeted treatment for cutaneous leishmaniasis) is a new Horizon 2020-funded project which aims to reduce the burden of Neglected Infectious Diseases (NID) and its social and economic impacts. Horizon 2020, the European Union’s (EU) research and innovation programme, helps to bridge the gap between preclinical and clinical development and thus helps to advance promising new drug candidates along the development pipeline. The TT4CL consortium, which brings together partners from academia and industry in Europe and disease-endemic countries, has been awarded EUR3.75 million to develop an oral treatment, D121, against one of the most neglected tropical diseases, cutaneous leishmaniasis.

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?